RNA editing is the next frontier in gene therapy—here’s what you need to know

The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular degeneration that causes vision loss in millions of older people worldwide.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup